ClinicalTrials.gg
RecruitingNCT07075601BIOVALVUpdated Jun 1, 2026

Non-interventional Study Exploring the Composition of the Valvular Microbiota of Patients Undergoing Cardiac Surgery

An interventional study of Take 1 ml of blood and DNA sequencing in Valvulopathy, Cardiac Surgery and Microbiota, sponsored by University Hospital, Toulouse. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 48 studies in Heart Valve Diseases with a site in France — 16 open to participants now, 22 under way, 1 of them phase 3. Heart Valve Diseases · France.

Planned enrollment
20th of 31
200 · median 228
Started
2025
with 2 others
No phase
27 of 48
5 open now
Primary completion
2029-08
later than 18 of 21 live
Registered
46th of 48
by date
Lead sponsor
2 of 48
University Hospital, Toulouse

Among the 48 studies in Heart Valve Diseases with a site in France, this one is the 20th largest by planned enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2025, is one of 27 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 46th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

16 of the 48 studies in Heart Valve Diseases with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in France, or all of them as a file.
02

Study summary

The prevalence of aortic valve disease is increasing, with these valvulopathies present in half of individuals over the age of 65.

Oberbach A. et al (1) demonstrated the presence of microbiota in 52% of cases of explanted aortic valves. One current hypothesis is the role of this microbiota in the pathophysiology of these degenerative valve diseases. This microbiota is probably not completely eradicated after resection of the native valve and implantation of a conventional prosthesis; it is even left in place during percutaneous aortic valve implantation, during which the prosthesis is deployed within the native valve. It could therefore also play a role in the occurrence of postoperative complications and the degeneration or thrombosis of a bioprosthesis.

Furthermore, recent clinical and epidemiological studies have shown a link between oral infections and cardiovascular diseases. As recommended by the HAS, these patients require multidisciplinary care, involving cardiologists, cardiac surgeons and general practitioners, as well as careful oral and dental care and monitoring provided by specialists in oral pathologies and oral care. The accumulation of bacterial plaque on the surface of the tooth and certain oral bacteria causes the development of periodontal pockets which are characteristic of periodontitis. Bacteria, microbial products and inflammatory mediators produced locally can then enter the bloodstream and affect distant organs such as the cardiovascular system. The recommendations of the European Society of Cardiology are therefore to carry out regular oral and dental consultations to prevent the risk of infection. Therefore, within the Toulouse University Hospital, a care network has been set up for patients with cardiovascular pathologies, in order to improve their access to dental care, screening and management of oral diseases. For the past year, patients hospitalized in the cardiology departments have been seen in consultation in the dental department of the Toulouse University Hospital.

03

Conditions studied

  • Valvulopathy
  • Cardiac Surgery
  • Microbiota

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient.
  • Present an indication for cardiac surgery that requires explantation of the aortic valve.
  • Be able to receive information about the study process and understand the study participation information form.
  • State their non-opposition to participating in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients infected with
  • Age under 18
  • Under court supervision, guardianship, or curatorship
  • Patients with a history of infective endocarditis.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Patients with an indication for cardiac surgery

    Patients with an indication for cardiac surgery during which the aortic valve is explanted.

    Biological: Take 1 ml of blood · Biological: DNA sequencing · Procedure: Valve collection (healthcare waste) · Other: Collection of serious post-operative complications

Interventions

  • BiologicalTake 1 ml of blood

    Take 1 ml of blood

  • BiologicalDNA sequencing

    DNA sequencing

  • ProcedureValve collection (healthcare waste)

    Valve collection (healthcare waste)

  • OtherCollection of serious post-operative complications

    Collection of serious post-operative complications

06

What researchers measure

Primary outcomes

  1. Occurrence of a serious postoperative complication

    Number of ischemic or hemorrhagic strokes; re-intervention, infective endocarditis, aortic bioprosthesis degeneration, aortic bioprosthesis thrombosis, mortality, surgical site infection requiring repeat surgery

    Time frame: 48 months

Secondary outcomes

  1. Determine the microbiological composition of saliva

    Determine the components of the salivary microbiota

    Time frame: 48 months

  2. Determine the components of the microbiota of periodontal plaque

    Determine the components of the microbiota of periodontal plaque

    Time frame: 48 months

  3. Oral health assessment

    Oral health assessment using the oral health assessment questionnaire called "Oral Study" which asks questions about the use of a toothbrush, interdental brushes, the frequency of visits to the dentist, and the use of mouthwash.

    Time frame: 48 months

  4. Evaluation of hygiene and dietary habits

    Assessment of dietary habits using a questionnaire on eating habits and the frequency of consumption of certain foods (bread, rusks, rice, pasta, vegetables, fruits, dairy products, fish, meat) with multiple choices between: Several times a day - Once a day - Several times a week - Once or twice a month - Never

    Time frame: 48 months

  5. Determine the inflammatory composition of saliva

    Determining inflammatory molecules in saliva

    Time frame: 48 months

  6. Determine the immune composition of saliva

    Determine the immune cells and molecules found in saliva

    Time frame: 48 months

  7. Determine the microbiological composition of feces

    Determine the molecules that make up the fecal microbiota

    Time frame: 48 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Aug 2029, 45 months after the start.

Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 45 months is above that.

Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2025
First posted
Jul 20, 2025
StartActual
Nov 19, 2025
Primary completionEst.
Aug 31, 2029
CompletionEst.
Aug 31, 2029
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07075601
Responsible party
Sponsor
First posted
Jul 20, 2025
Start date
Nov 19, 2025
Primary completion
Aug 31, 2029 (estimated)
Completion
Aug 31, 2029 (estimated)
Last update
Jun 1, 2026

Study contacts

Bertrand MARCHEIX, MD
Contact
marcheix.b@chu-toulouse.fr
5 61 32 37 18 ext. +33
Audrey TOMASIK
Contact
tomasik.a@chu-toulouse.fr
5 61 77 85 97 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion